Peripheral Vascular Interventional Devices Market by Device Type (Atherectomy Devices, Balloon Catheters, Embolic Agents), Technology (Bare Metal, Bioabsorbable, Drug Coated), Application, End User, Distribution Channel - Global Forecast 2026-2032
Description
The Peripheral Vascular Interventional Devices Market was valued at USD 1.52 billion in 2025 and is projected to grow to USD 1.57 billion in 2026, with a CAGR of 4.68%, reaching USD 2.10 billion by 2032.
A compelling introduction framing how clinical imperatives, material innovations, and health policy converge to redefine peripheral vascular interventional devices
The peripheral vascular interventional devices field stands at a pivotal intersection of clinical need, engineering innovation, and evolving health policy. In recent years, clinicians have increasingly adopted minimally invasive approaches to address arterial and venous pathologies, prompting device manufacturers and health systems to re-evaluate product portfolios, service delivery models, and procedural pathways. Concurrently, advances in materials science and drug delivery have elevated device performance expectations, while reimbursement dynamics and site-of-care shifts exert continuous influence on adoption patterns.
Consequently, stakeholders must navigate an environment where clinical performance, procedural efficiency, and supply chain robustness each determine competitive positioning. This introduction frames the principal forces driving contemporary practice, summarizes the types of devices that shape procedural choices, and situates innovation trends alongside regulatory and commercial realities. The picture that emerges is one of steady technological maturation tempered by the need for pragmatic responses to policy, procurement, and operational constraints.
How procedural migration, materials innovation, supply chain resilience, and outcomes-based reimbursement are collectively transforming the peripheral vascular devices landscape
Transformative shifts are reshaping how clinicians, manufacturers, and payers approach peripheral vascular interventions. First, procedural migration toward ambulatory surgical centers and hybrid clinic-surgical models is increasing demand for devices designed for rapid deployment and simplified inventory management. Secondly, material and drug delivery innovations-such as bioabsorbable scaffolds and targeted drug-coating technologies-are prompting reassessment of long-term outcomes versus short-term procedural efficiency. These technical developments are complemented by digital health integration, where procedural data capture and remote monitoring inform follow-up care and real-world evidence generation.
Moreover, supply chain resilience has ascended the strategic agenda after recent global disruptions, encouraging manufacturers to diversify sourcing and invest in regional manufacturing capabilities. Payer behavior is also shifting, with a greater emphasis on value-based arrangements and outcomes-driven contracting that prioritize durable clinical benefit and total cost of care. Taken together, these forces are accelerating consolidation among suppliers, catalyzing strategic partnerships, and prioritizing products that demonstrate measurable improvements in patient outcomes and care pathways.
An incisive analysis of how the 2025 United States tariffs reshaped supply chains, cost structures, and procurement behavior across peripheral vascular device value chains
The cumulative impact of United States tariffs implemented in 2025 has introduced a complex set of operational and strategic considerations for manufacturers, distributors, and health systems involved in peripheral vascular devices. Tariff-driven input cost increases have pressured margins for device producers that rely on imported raw materials or finished components. As a result, some manufacturers have accelerated efforts to localize supply chains, re-negotiate supplier contracts, and evaluate alternative materials that achieve comparable clinical performance while mitigating tariff exposure. These adaptive measures, in turn, influence product pricing strategies and procurement negotiations with healthcare providers.
In parallel, distributors and hospitals have re-examined portfolio rationalization, prioritizing devices with stable supply and predictable landed costs to minimize inventory risk. Regulatory and customs complexities introduced by tariff policies have also increased the administrative burden associated with cross-border logistics, prompting greater investments in compliance capability. Importantly, tariff effects have not been uniform across device categories; capital-intensive products that incorporate high-value materials experienced different pressures than lower-cost disposables. Taken together, the 2025 tariff environment has reinforced the strategic importance of supply chain transparency, cost-to-serve analysis, and scenario planning for all stakeholders operating within the United States market.
A deep segmentation-driven perspective revealing how device types, clinical applications, end users, technologies, and distribution choices determine adoption pathways and commercial success
Insightful segmentation analysis reveals distinct commercial and clinical dynamics across device types, applications, end users, technologies, and distribution approaches. When examining device type, the market encompasses atherectomy devices, balloon catheters, embolic agents, embolic protection devices, IVC filters, and stents; within atherectomy, directional, laser, orbital, and rotational subtypes each carry specific procedural indications and capital equipment considerations, while balloon catheters include drug coated balloons and plain balloon catheters that differ in downstream follow-up and reimbursement implications. Embolic agents span embolic coils, embolic particles, and liquid embolics, each suited to particular embolization scenarios, and embolic protection devices separate into distal and proximal varieties to address anatomic and flow-related demands. IVC filters are manufactured as permanent or retrievable designs with divergent clinical risk-benefit profiles, and stent technologies include bare metal and drug-eluting options with differing durability and restenosis characteristics.
From an application perspective, device selection and procedural protocols vary across hemodialysis access, peripheral arterial disease, and venous disease. Hemodialysis access management differentiates between AV fistula maintenance and graft maintenance, where device durability and repeatability of interventions are key considerations. Peripheral arterial disease care distinguishes critical limb ischemia from intermittent claudication in terms of urgency and long-term limb salvage goals, and venous disease treatment navigates chronic venous insufficiency, deep vein thrombosis, and varicose vein presentations that require tailored device solutions. End users comprise ambulatory surgical centers, hospitals, and specialty clinics, with site-of-care considerations driving preference for devices that balance procedural complexity, capital outlay, and throughput efficiency. Technological segmentation across bare metal, bioabsorbable, and drug coated platforms underscores trade-offs between immediate mechanical support and long-term vessel healing. Finally, distribution channel dynamics split between direct sales and distributor sales, affecting post-market support, training availability, and contracting flexibility. Collectively, these segmentation lenses illuminate where clinical demand, purchasing behavior, and innovation converge to create differentiated opportunities and operational constraints.
Granular regional insights explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market characteristics uniquely influence commercialization and regulatory strategies
Regional dynamics shape adoption patterns, regulatory interactions, and supply chain strategies in markedly different ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems feature a mix of private and public funding models that influence reimbursement complexity and the pace at which novel devices enter clinical use; procurement decision-making often emphasizes demonstrated health economic value and post-market surveillance data. By contrast, Europe Middle East & Africa presents heterogeneous regulatory and market access environments, where regional centers of excellence drive adoption in advanced markets while emerging economies prioritize cost-effective solutions and supply stability.
Asia-Pacific exhibits a broad spectrum of maturity, with some markets advancing rapidly in minimally invasive procedural volume and local manufacturing capacity, while others remain focused on improving access to established, durable devices. Across these regions, localization of manufacturing, regional regulatory harmonization efforts, and the emergence of new clinical leaders all affect product strategy. Consequently, tailored commercialization plans that account for reimbursement pathways, clinician training needs, and logistics capabilities are essential to achieve sustainable market presence in each geographic cohort.
Key firm-level competitive intelligence detailing how innovation, partnerships, regulatory strategy, and manufacturing scale determine leadership in peripheral vascular devices
Competitive dynamics in the peripheral vascular device sector are characterized by product differentiation, strategic partnerships, and targeted investments in regulatory approvals and manufacturing scalability. Market leaders and emerging challengers alike are prioritizing therapies that deliver demonstrable clinical advantages, streamline procedural workflows, and reduce total cost of care. Partnerships between device firms and technology companies are increasingly common, particularly where digital tools can enhance procedural planning, post-procedure monitoring, and real-world evidence collection that supports reimbursement conversations.
In addition, contract manufacturing and strategic sourcing arrangements play an outsized role in enabling smaller innovators to scale while larger firms pursue manufacturing redundancy and vertical integration to protect supply continuity. Regulatory strategy remains a defining element of competitive positioning; timely approvals and post-market safety data not only enable market entry but also reinforce purchasing confidence among health systems. Finally, corporate development activity-ranging from bolt-on acquisitions to broader alliances-continues to reconfigure the supplier landscape as organizations seek complementary technologies, expanded clinical footprints, and enhanced distribution capabilities.
Practical and actionable strategic recommendations for device manufacturers and health systems to align innovation, supply resilience, and payer engagement for sustainable growth
Industry leaders should adopt a multi-pronged strategy that aligns product innovation with supply chain resilience, payer engagement, and clinician-centric commercialization. First, prioritizing design choices that simplify procedural workflows and reduce inventory complexity will enhance adoption in ambulatory and hospital settings alike while lowering the total cost of ownership for purchasers. Second, investing in diversified sourcing, regional manufacturing footprints, and supplier risk management practices will mitigate exposure to future tariff or trade disruptions and preserve continuity for critical device lines.
Third, proactive engagement with payers to demonstrate clinical and economic value through well-designed outcomes studies and real-world data initiatives will facilitate coverage decisions and support value-based contracting. Fourth, strengthening clinician training and post-market support through integrated digital platforms and hands-on education will accelerate safe adoption and generate essential performance data. Finally, pursuing collaborative arrangements-whether through strategic partnerships, targeted acquisitions, or co-development agreements-will allow firms to fill capability gaps more rapidly than organic development alone. Taken together, these actions will position industry participants to capitalize on clinical demand while managing commercial and operational risk.
A transparent and robust research methodology combining clinical expert interviews, secondary regulatory and technical review, and triangulated analytical techniques to ensure reliable insights
The research methodology underpinning this analysis combines qualitative expert interviews, structured primary research with clinical and procurement stakeholders, and rigorous secondary research across regulatory filings, technical literature, and public policy documents. Primary engagements included conversations with interventional physicians, supply chain managers, and hospital procurement leaders to gather insights on procedural trends, device usability, and purchasing criteria. Secondary sources were systematically reviewed to understand device classifications, regulatory precedents, and material science advancements that influence product development choices.
Analytical techniques employed include comparative device attribute mapping, scenario analysis to assess tariff and supply chain outcomes, and segmentation-driven commercial opportunity assessment. Triangulation across multiple evidence streams was used to validate findings and ensure that conclusions reflect both clinical realities and commercial imperatives. Where applicable, sensitivity checks and cross-validation with industry experts were conducted to refine interpretations and ensure balanced, credible recommendations.
A concise conclusion synthesizing how clinical innovation, policy pressures, and supply resilience combine to define winners in the peripheral vascular device market
The conclusion synthesizes the strategic implications of technological progress, policy shifts, and evolving care delivery models for stakeholders in the peripheral vascular interventional devices arena. Technological innovations-ranging from advanced atherectomy subtypes to drug-coated delivery platforms-are progressively blurring the lines between device categories and creating new clinical pathways that favor minimally invasive, repeatable interventions. Policy dynamics and tariff-related supply chain considerations have elevated the importance of cost visibility, regional sourcing, and procurement agility, while payer demands for outcomes-driven evidence are intensifying expectations around post-market data generation.
Ultimately, success in this environment will depend on the ability of manufacturers and providers to integrate clinical evidence, operational resilience, and intelligent commercialization strategies. Organizations that align device design with procedural efficiency, invest in supply chain redundancy, and proactively demonstrate value to payers and clinicians will be best positioned to capture durable demand and support improved patient outcomes.
Note: PDF & Excel + Online Access - 1 Year
A compelling introduction framing how clinical imperatives, material innovations, and health policy converge to redefine peripheral vascular interventional devices
The peripheral vascular interventional devices field stands at a pivotal intersection of clinical need, engineering innovation, and evolving health policy. In recent years, clinicians have increasingly adopted minimally invasive approaches to address arterial and venous pathologies, prompting device manufacturers and health systems to re-evaluate product portfolios, service delivery models, and procedural pathways. Concurrently, advances in materials science and drug delivery have elevated device performance expectations, while reimbursement dynamics and site-of-care shifts exert continuous influence on adoption patterns.
Consequently, stakeholders must navigate an environment where clinical performance, procedural efficiency, and supply chain robustness each determine competitive positioning. This introduction frames the principal forces driving contemporary practice, summarizes the types of devices that shape procedural choices, and situates innovation trends alongside regulatory and commercial realities. The picture that emerges is one of steady technological maturation tempered by the need for pragmatic responses to policy, procurement, and operational constraints.
How procedural migration, materials innovation, supply chain resilience, and outcomes-based reimbursement are collectively transforming the peripheral vascular devices landscape
Transformative shifts are reshaping how clinicians, manufacturers, and payers approach peripheral vascular interventions. First, procedural migration toward ambulatory surgical centers and hybrid clinic-surgical models is increasing demand for devices designed for rapid deployment and simplified inventory management. Secondly, material and drug delivery innovations-such as bioabsorbable scaffolds and targeted drug-coating technologies-are prompting reassessment of long-term outcomes versus short-term procedural efficiency. These technical developments are complemented by digital health integration, where procedural data capture and remote monitoring inform follow-up care and real-world evidence generation.
Moreover, supply chain resilience has ascended the strategic agenda after recent global disruptions, encouraging manufacturers to diversify sourcing and invest in regional manufacturing capabilities. Payer behavior is also shifting, with a greater emphasis on value-based arrangements and outcomes-driven contracting that prioritize durable clinical benefit and total cost of care. Taken together, these forces are accelerating consolidation among suppliers, catalyzing strategic partnerships, and prioritizing products that demonstrate measurable improvements in patient outcomes and care pathways.
An incisive analysis of how the 2025 United States tariffs reshaped supply chains, cost structures, and procurement behavior across peripheral vascular device value chains
The cumulative impact of United States tariffs implemented in 2025 has introduced a complex set of operational and strategic considerations for manufacturers, distributors, and health systems involved in peripheral vascular devices. Tariff-driven input cost increases have pressured margins for device producers that rely on imported raw materials or finished components. As a result, some manufacturers have accelerated efforts to localize supply chains, re-negotiate supplier contracts, and evaluate alternative materials that achieve comparable clinical performance while mitigating tariff exposure. These adaptive measures, in turn, influence product pricing strategies and procurement negotiations with healthcare providers.
In parallel, distributors and hospitals have re-examined portfolio rationalization, prioritizing devices with stable supply and predictable landed costs to minimize inventory risk. Regulatory and customs complexities introduced by tariff policies have also increased the administrative burden associated with cross-border logistics, prompting greater investments in compliance capability. Importantly, tariff effects have not been uniform across device categories; capital-intensive products that incorporate high-value materials experienced different pressures than lower-cost disposables. Taken together, the 2025 tariff environment has reinforced the strategic importance of supply chain transparency, cost-to-serve analysis, and scenario planning for all stakeholders operating within the United States market.
A deep segmentation-driven perspective revealing how device types, clinical applications, end users, technologies, and distribution choices determine adoption pathways and commercial success
Insightful segmentation analysis reveals distinct commercial and clinical dynamics across device types, applications, end users, technologies, and distribution approaches. When examining device type, the market encompasses atherectomy devices, balloon catheters, embolic agents, embolic protection devices, IVC filters, and stents; within atherectomy, directional, laser, orbital, and rotational subtypes each carry specific procedural indications and capital equipment considerations, while balloon catheters include drug coated balloons and plain balloon catheters that differ in downstream follow-up and reimbursement implications. Embolic agents span embolic coils, embolic particles, and liquid embolics, each suited to particular embolization scenarios, and embolic protection devices separate into distal and proximal varieties to address anatomic and flow-related demands. IVC filters are manufactured as permanent or retrievable designs with divergent clinical risk-benefit profiles, and stent technologies include bare metal and drug-eluting options with differing durability and restenosis characteristics.
From an application perspective, device selection and procedural protocols vary across hemodialysis access, peripheral arterial disease, and venous disease. Hemodialysis access management differentiates between AV fistula maintenance and graft maintenance, where device durability and repeatability of interventions are key considerations. Peripheral arterial disease care distinguishes critical limb ischemia from intermittent claudication in terms of urgency and long-term limb salvage goals, and venous disease treatment navigates chronic venous insufficiency, deep vein thrombosis, and varicose vein presentations that require tailored device solutions. End users comprise ambulatory surgical centers, hospitals, and specialty clinics, with site-of-care considerations driving preference for devices that balance procedural complexity, capital outlay, and throughput efficiency. Technological segmentation across bare metal, bioabsorbable, and drug coated platforms underscores trade-offs between immediate mechanical support and long-term vessel healing. Finally, distribution channel dynamics split between direct sales and distributor sales, affecting post-market support, training availability, and contracting flexibility. Collectively, these segmentation lenses illuminate where clinical demand, purchasing behavior, and innovation converge to create differentiated opportunities and operational constraints.
Granular regional insights explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market characteristics uniquely influence commercialization and regulatory strategies
Regional dynamics shape adoption patterns, regulatory interactions, and supply chain strategies in markedly different ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems feature a mix of private and public funding models that influence reimbursement complexity and the pace at which novel devices enter clinical use; procurement decision-making often emphasizes demonstrated health economic value and post-market surveillance data. By contrast, Europe Middle East & Africa presents heterogeneous regulatory and market access environments, where regional centers of excellence drive adoption in advanced markets while emerging economies prioritize cost-effective solutions and supply stability.
Asia-Pacific exhibits a broad spectrum of maturity, with some markets advancing rapidly in minimally invasive procedural volume and local manufacturing capacity, while others remain focused on improving access to established, durable devices. Across these regions, localization of manufacturing, regional regulatory harmonization efforts, and the emergence of new clinical leaders all affect product strategy. Consequently, tailored commercialization plans that account for reimbursement pathways, clinician training needs, and logistics capabilities are essential to achieve sustainable market presence in each geographic cohort.
Key firm-level competitive intelligence detailing how innovation, partnerships, regulatory strategy, and manufacturing scale determine leadership in peripheral vascular devices
Competitive dynamics in the peripheral vascular device sector are characterized by product differentiation, strategic partnerships, and targeted investments in regulatory approvals and manufacturing scalability. Market leaders and emerging challengers alike are prioritizing therapies that deliver demonstrable clinical advantages, streamline procedural workflows, and reduce total cost of care. Partnerships between device firms and technology companies are increasingly common, particularly where digital tools can enhance procedural planning, post-procedure monitoring, and real-world evidence collection that supports reimbursement conversations.
In addition, contract manufacturing and strategic sourcing arrangements play an outsized role in enabling smaller innovators to scale while larger firms pursue manufacturing redundancy and vertical integration to protect supply continuity. Regulatory strategy remains a defining element of competitive positioning; timely approvals and post-market safety data not only enable market entry but also reinforce purchasing confidence among health systems. Finally, corporate development activity-ranging from bolt-on acquisitions to broader alliances-continues to reconfigure the supplier landscape as organizations seek complementary technologies, expanded clinical footprints, and enhanced distribution capabilities.
Practical and actionable strategic recommendations for device manufacturers and health systems to align innovation, supply resilience, and payer engagement for sustainable growth
Industry leaders should adopt a multi-pronged strategy that aligns product innovation with supply chain resilience, payer engagement, and clinician-centric commercialization. First, prioritizing design choices that simplify procedural workflows and reduce inventory complexity will enhance adoption in ambulatory and hospital settings alike while lowering the total cost of ownership for purchasers. Second, investing in diversified sourcing, regional manufacturing footprints, and supplier risk management practices will mitigate exposure to future tariff or trade disruptions and preserve continuity for critical device lines.
Third, proactive engagement with payers to demonstrate clinical and economic value through well-designed outcomes studies and real-world data initiatives will facilitate coverage decisions and support value-based contracting. Fourth, strengthening clinician training and post-market support through integrated digital platforms and hands-on education will accelerate safe adoption and generate essential performance data. Finally, pursuing collaborative arrangements-whether through strategic partnerships, targeted acquisitions, or co-development agreements-will allow firms to fill capability gaps more rapidly than organic development alone. Taken together, these actions will position industry participants to capitalize on clinical demand while managing commercial and operational risk.
A transparent and robust research methodology combining clinical expert interviews, secondary regulatory and technical review, and triangulated analytical techniques to ensure reliable insights
The research methodology underpinning this analysis combines qualitative expert interviews, structured primary research with clinical and procurement stakeholders, and rigorous secondary research across regulatory filings, technical literature, and public policy documents. Primary engagements included conversations with interventional physicians, supply chain managers, and hospital procurement leaders to gather insights on procedural trends, device usability, and purchasing criteria. Secondary sources were systematically reviewed to understand device classifications, regulatory precedents, and material science advancements that influence product development choices.
Analytical techniques employed include comparative device attribute mapping, scenario analysis to assess tariff and supply chain outcomes, and segmentation-driven commercial opportunity assessment. Triangulation across multiple evidence streams was used to validate findings and ensure that conclusions reflect both clinical realities and commercial imperatives. Where applicable, sensitivity checks and cross-validation with industry experts were conducted to refine interpretations and ensure balanced, credible recommendations.
A concise conclusion synthesizing how clinical innovation, policy pressures, and supply resilience combine to define winners in the peripheral vascular device market
The conclusion synthesizes the strategic implications of technological progress, policy shifts, and evolving care delivery models for stakeholders in the peripheral vascular interventional devices arena. Technological innovations-ranging from advanced atherectomy subtypes to drug-coated delivery platforms-are progressively blurring the lines between device categories and creating new clinical pathways that favor minimally invasive, repeatable interventions. Policy dynamics and tariff-related supply chain considerations have elevated the importance of cost visibility, regional sourcing, and procurement agility, while payer demands for outcomes-driven evidence are intensifying expectations around post-market data generation.
Ultimately, success in this environment will depend on the ability of manufacturers and providers to integrate clinical evidence, operational resilience, and intelligent commercialization strategies. Organizations that align device design with procedural efficiency, invest in supply chain redundancy, and proactively demonstrate value to payers and clinicians will be best positioned to capture durable demand and support improved patient outcomes.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Peripheral Vascular Interventional Devices Market, by Device Type
- 8.1. Atherectomy Devices
- 8.1.1. Directional Atherectomy Devices
- 8.1.2. Laser Atherectomy Devices
- 8.1.3. Orbital Atherectomy Devices
- 8.1.4. Rotational Atherectomy Devices
- 8.2. Balloon Catheters
- 8.2.1. Drug Coated Balloons
- 8.2.2. Plain Balloon Catheters
- 8.3. Embolic Agents
- 8.3.1. Embolic Coils
- 8.3.2. Embolic Particles
- 8.3.3. Liquid Embolics
- 8.4. Embolic Protection Devices
- 8.4.1. Distal Embolic Protection Devices
- 8.4.2. Proximal Embolic Protection Devices
- 8.5. IVC Filters
- 8.5.1. Permanent IVC Filters
- 8.5.2. Retrievable IVC Filters
- 8.6. Stents
- 8.6.1. Bare Metal
- 8.6.2. Drug Eluting
- 9. Peripheral Vascular Interventional Devices Market, by Technology
- 9.1. Bare Metal
- 9.2. Bioabsorbable
- 9.3. Drug Coated
- 10. Peripheral Vascular Interventional Devices Market, by Application
- 10.1. Hemodialysis Access
- 10.1.1. AV Fistula Maintenance
- 10.1.2. Graft Maintenance
- 10.2. Peripheral Arterial Disease
- 10.2.1. Critical Limb Ischemia
- 10.2.2. Intermittent Claudication
- 10.3. Venous Disease
- 10.3.1. Chronic Venous Insufficiency
- 10.3.2. Deep Vein Thrombosis
- 10.3.3. Varicose Veins
- 11. Peripheral Vascular Interventional Devices Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Hospitals
- 11.3. Specialty Clinics
- 12. Peripheral Vascular Interventional Devices Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Distributor Sales
- 13. Peripheral Vascular Interventional Devices Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Peripheral Vascular Interventional Devices Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Peripheral Vascular Interventional Devices Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. United States Peripheral Vascular Interventional Devices Market
- 17. China Peripheral Vascular Interventional Devices Market
- 18. Competitive Landscape
- 18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
- 18.2. Recent Developments & Impact Analysis, 2025
- 18.3. Product Portfolio Analysis, 2025
- 18.4. Benchmarking Analysis, 2025
- 18.5. Abbott Laboratories
- 18.6. AngioDynamics, Inc.
- 18.7. Becton, Dickinson and Company
- 18.8. BIOTRONIK SE & Co. KG
- 18.9. Boston Scientific Corporation
- 18.10. C.R. Bard, Inc.
- 18.11. Cordis Corporation
- 18.12. Endologix, Inc.
- 18.13. InspireMD, Inc.
- 18.14. iVascular S.L.U.
- 18.15. Lepu Medical Technology Co., Ltd.
- 18.16. Medtronic plc
- 18.17. Merit Medical Systems, Inc.
- 18.18. MicroPort Scientific Corporation
- 18.19. Penumbra, Inc.
- 18.20. Philips Healthcare
- 18.21. Shockwave Medical, Inc.
- 18.22. Teleflex Incorporated
- 18.23. Terumo Corporation
- 18.24. W. L. Gore & Associates, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
